Thompson Davis & Co’s Bristol-Myers Squibb BMY Stock Holding History

Thompson Davis & Co’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$51K	Buy	820 +1	+0.1%	+$59	0.11%	195
2018 Q2	$45K	Hold	819	–	–	0.11%	208
2018 Q1	$52K	Buy	819 +126	+18%	+$8.11K	0.14%	162
2017 Q4	$42K	Sell	693 -154	-18%	-$9.63K	0.1%	205
2017 Q3	$54K	Buy	847 +280	+49%	+$16.3K	0.1%	218
2017 Q2	$32K	Hold	567	–	–	0.05%	319
2017 Q1	$31K	Sell	567 -4,087	-88%	-$224K	0.04%	346
2016 Q4	$272K	Buy	4,654 +1	+0%	+$55	0.45%	51
2016 Q3	$251K	Sell	4,653 -500	-10%	-$32.1K	0.44%	53
2016 Q2	$379K	Buy	5,153 +1,049	+26%	+$74.1K	0.6%	30
2016 Q1	$262K	Buy	4,104 +50	+1%	+$3.15K	0.39%	64
2015 Q4	$279K	Sell	4,054 -1,352	-25%	-$89.3K	0.39%	58
2015 Q3	$320K	Sell	5,406 -195	-3%	-$12.4K	0.45%	56
2015 Q2	$373K	Sell	5,601 -28	-0.5%	-$1.84K	0.43%	43
2015 Q1	$363K	Sell	5,629 -6,534	-54%	-$409K	0.44%	39
2014 Q4	$718K	Buy	12,163 +5,407	+80%	+$305K	0.83%	23
2014 Q3	$346K	Buy	6,756 +868	+15%	+$43.4K	0.45%	45
2014 Q2	$286K	Buy	5,888 +504	+9%	+$24.8K	0.41%	59
2014 Q1	$280K	Buy	5,384 +103	+2%	+$5.48K	0.46%	50
2013 Q4	$281K	Buy	+5,281	New	+$269K	0.42%	57

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Thompson Davis & Co's BMY Position: Q3 2018 in Review

Thompson Davis & Co increased its Bristol-Myers Squibb (BMY) stake by 0.12% in Q3 2018, buying an estimated $59 and bringing the position to 820 shares worth $51K. The position accounts for 0.11% of the portfolio, ranked #195.

Thompson Davis & Co first reported a position in BMY in Q4 2013 and has held it in 20 quarters since. The position peaked at $718K in Q4 2014. 1,729 funds tracked by Wall St. Rank hold BMY as of Q3 2018.

Thompson Davis & Co held 820 shares of Bristol-Myers Squibb worth $51K as of Q3 2018.
Thompson Davis & Co bought 1 Bristol-Myers Squibb share in Q3 2018, an estimated $59.
Bristol-Myers Squibb made up 0.11% of Thompson Davis & Co's portfolio in Q3 2018, its #195 holding.
Thompson Davis & Co first reported a position in Bristol-Myers Squibb in Q4 2013 and has held it in 20 quarters since.
Thompson Davis & Co's Bristol-Myers Squibb position peaked at $718K in Q4 2014.
1,729 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.